Effect of Curcumin, Vitamin D and herbal oil on Multiple Sclerosis

Evaluation of Clinical and Metabolic Responses to Combined Effect of Curcumin, Cholecalciferol, and Evening Primrose oil in Patients with Multiple Sclerosis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170430033730N6

Enrollment

Registered

2019-03-25

Start date

2019-04-13

Completion date

Unknown

Last updated

2019-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis. Multiple sclerosis

Interventions

Intervention 1: Intervention group: Two sub-gels containing (80 mg curcumin + 1000 IUD3) and Primrose oil (1000 mg) will receive daily for twelve weeks. Intervention 2: Control group: Two sub-gels o

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients with MS

Exclusion criteria

Exclusion criteria: Patients who do not want to cooperate; Patients who have others complications such as: kidney disease? neuropathy and retinopathy;Patients with hypo and/or hyperthyroidism are excluded from this study. Patients with other inflammatory conditions such as allergies and autoimmune diseases pregnant women

Design outcomes

Primary

Measure	Time frame
Hs-CRP. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Elisa.;IL-18. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Elisa.	—

Secondary

Measure	Time frame
T25FW test. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Physical examination.;9-HPT Test. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Physical examination.;FBS. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Insulin. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.;TG. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Cholesterol. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;HDL. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;LDL. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;AST. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;ALT. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;ALKP. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;TP. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Alb. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;BUN. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;???????. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method	—

Measure

Time frame

T25FW test. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Physical examination.;9-HPT Test. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Physical examination.;FBS. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Insulin. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.;TG. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Cholesterol. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;HDL. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;LDL. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;AST. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;ALT. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;ALKP. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;TP. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Alb. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;BUN. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;???????. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyyed Mehdi Mirhashemi

Qazvin University of Medical Sciences

mirhashemism@gmail.com+98 28 3333 6001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026